Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.011 AUD | +10.00% | -.--% | -.--% |
Feb. 26 | Exopharm Limited Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
Nov. 28 | Exopharm to Cut CEO Role Amid Cost Reductions | MT |
Sales 2022 | 4.21M 2.74M | Sales 2023 | 3.39M 2.21M | Capitalization | 3.52M 2.29M |
---|---|---|---|---|---|
Net income 2022 | -10M -6.51M | Net income 2023 | -7M -4.56M | EV / Sales 2022 | 4.6 x |
Net cash position 2022 | 1.1M 719K | Net cash position 2023 | 109K 71.19K | EV / Sales 2023 | 1 x |
P/E ratio 2022 |
-2.03
x | P/E ratio 2023 |
-0.22
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 61.79% |
1 day | +10.00% | ||
6 months | +10.00% |
Managers | Title | Age | Since |
---|---|---|---|
Ian Dixon
FOU | Founder | - | 12-12-31 |
Alison Mew
PRN | Corporate Officer/Principal | 66 | 20-09-14 |
David Franks
SEC | Corporate Secretary | 53 | 21-09-29 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mark Davies
CHM | Chairman | - | 23-06-21 |
Ian Dixon
FOU | Founder | - | 12-12-31 |
Clarke Barlow
BRD | Director/Board Member | 43 | 23-02-21 |
1st Jan change | Capi. | |
---|---|---|
-.--% | 3.15M | |
+9.30% | 46.03B | |
+52.73% | 44.55B | |
+7.15% | 40.8B | |
-8.78% | 28.25B | |
+18.68% | 27.71B | |
-21.92% | 18.82B | |
+14.62% | 13.91B | |
+31.85% | 12.43B | |
+4.47% | 10.81B |